Medical Cannabis and Pain: The Evidence Base
This evidence summary presents a structured, clinically focused review of the role of cannabis-based medicinal products (CBMPs) in the management of pain. Developed by the Medical Cannabis Clinicians Society, it brings together current research, clinical insight, and real-world data to support informed decision-making in practice. Written in clear, accessible language, it is intended for clinicians, healthcare professionals, educators, and readers seeking a grounded understanding of this evolving area.
The publication examines the use of cannabinoids, particularly THC and CBD, across a range of pain conditions, including chronic, neuropathic, and cancer-related pain. It draws on a substantial evidence base of 264 references, with 124 studies analysed and summarised in detail for the reader. These include randomised controlled trials, observational studies, open-label studies, and case reports, offering a balanced view of both controlled and real-world outcomes
Key areas of focus include pharmacological mechanisms, clinical outcomes, dosing considerations, and the balance between benefit and risk. The publication explores how cannabinoids interact with the endocannabinoid system to influence pain signalling, inflammation, and central processing, while also addressing issues such as tolerance, side effects, and drug interactions. It incorporates both controlled trials and real-world evidence, recognising the importance of observational data in a field where large-scale randomised trials remain limited.
This publication serves as a practical reference for clinicians integrating CBMPs into pain management. It supports evidence-based decision-making while acknowledging uncertainty, making it particularly relevant for those working in complex or treatment-resistant cases. As part of the wider MCCS Evidence Base Series, it contributes to a growing body of clinically relevant resources designed to support safe and consistent prescribing.
Content includes:
- Overview of pain classifications and underlying mechanisms
- Role of the endocannabinoid system in pain modulation
- Pharmacology of THC, CBD, and other cannabinoids
- 264 references, including 124 detailed study summaries
- Evidence from RCTs, observational studies, open-label studies, and case reports
- Application in chronic, neuropathic, and cancer-related pain
- Dosing approaches and titration strategies
- Safety profile, side effects, and drug interactions
- Considerations for long-term use and dependency risk
- UK prescribing context, including legal and regulatory factors
Format: Digital PDF
Length: 91 pages
Authors: Medical Cannabis Clinicians Society
Publisher: Medical Cannabis Clinicians Society (2026)
FAQ
Who is this publication for?
Clinicians, prescribers, pharmacists, educators, and informed readers interested in the clinical use of medical cannabis for pain.
What types of pain does it cover?
It addresses a range of conditions, including chronic non-cancer pain, neuropathic pain, and cancer-related pain.
How strong is the evidence base?
It includes 264 references overall, with 124 studies reviewed in detail, spanning RCTs, observational research, open-label studies, and case reports.
Does it cover safety and side effects?
Yes. It outlines common adverse effects, potential drug interactions, and considerations for monitoring and risk management.
Is UK clinical practice addressed?
Yes. It includes discussion of prescribing regulations, access challenges, and the current reliance on private clinics in the UK.
What makes this different from other resources?
It combines detailed evidence review with practical clinical context, translating research findings into usable insights for day-to-day practice.
Is prior knowledge required?
No. It is written to be accessible while still providing sufficient depth for clinical use.
Is the content independent?
Yes. It is produced by the Medical Cannabis Clinicians Society and is based on published research, expert clinical insight and current UK guidance.